Cervical dysplasia in a patient with multiple sclerosis treated with natalizumab.

Geneviève DurrieuQuentin DardonvilleMichel ClanetJean-Louis Montastruc

Published in: Fundamental & clinical pharmacology (2018)

We describe one report of a cervical dysplasia in a patient receiving natalizumab for multiple sclerosis. Other cases were identified in the WHO's global individual case safety report database, VigiBase® . These data underline the importance of monitoring HPV infection in patients with MS treated with natalizumab.

Keyphrases

multiple sclerosis
white matter
case report
high grade
emergency department
newly diagnosed
machine learning
adverse drug